key: cord-0762025-8dzh3uoc
authors: Fronza, Matteo; Thavendiranathan, Paaladinesh; Chan, Victor; Karur, Gauri Rani; Udell, Jacob A.; Wald, Rachel M.; Hong, Rachel; Hanneman, Kate
title: Myocardial Injury Pattern at MRI in COVID-19 Vaccine–associated Myocarditis
date: 2022-02-15
journal: Radiology
DOI: 10.1148/radiol.212559
sha: c1a7a96f6de401dcb7319c8a85b5c08e145eb46d
doc_id: 762025
cord_uid: 8dzh3uoc

BACKGROUND: There is limited data on the pattern and severity of myocardial injury in patients with COVID-19 vaccination associated myocarditis. PURPOSE: To describe myocardial injury following COVID-19 vaccination and to compare these findings to other causes of myocarditis. METHODS: In this retrospective cohort study, consecutive adult patients with myocarditis with at least one T1-based and at least one T2-based abnormality on cardiac MRI performed at a tertiary referral hospital between 2019-2021 were included. Patients were classified into one of three groups: myocarditis following COVID-19 vaccination, myocarditis following COVID-19 illness, and other myocarditis not associated COVID-19 vaccination or illness. RESULTS: Of the 92 included patients, 21 (22%) had myocarditis following COVID-19 vaccination (mean age 31 years ±14 [standard deviation]; 17 men; mRNA-1273 in 12 [57%] and BNT162b2 in 9 [43%]). Ten patients (11%) had myocarditis following COVID-19 illness (mean age 51 years ±14; 3 men), and 61 (66%) had other myocarditis (mean age 44 years ±18; 36 men). MRI findings in vaccine associated myocarditis included late gadolinium enhancement (LGE) in 17 (81%) and left ventricular dysfunction in 6 (29%). Compared with other causes of myocarditis, patients with vaccine associated myocarditis had higher left ventricular ejection fraction and less extensive LGE, even after controlling for age, sex, and duration between symptom onset and MRI. The most frequent location of LGE in all groups was subepicardial at the basal inferolateral wall, although septal involvement was less common in vaccine associated myocarditis. At short-term follow-up (median 22 [IQR 7-48] days), all patients with vaccine associated myocarditis were asymptomatic with no adverse events. CONCLUSIONS: Cardiac MRI demonstrated a similar pattern of myocardial injury in vaccine associated myocarditis compared to other causes, although abnormalities were less severe, with less frequent septal involvement, and no adverse events over short-term follow-up. See also the editorial by Raman and Neubauer.

Myocarditis is a non-ischemic inflammatory disease of the myocardium, with diverse causes, clinical patterns, and outcomes (1) . Characteristic features are inflammation and myocyte damage, which may be mediated both by direct invasion of the myocardium in the setting of viral infection and by the host's immune response (2) . Acute myocarditis is more common in men compared to women, although the incidence is difficult to establish as the clinical presentation is often non-specific and endomyocardial biopsy is not routinely performed (3).

Myocarditis following immunization is a rare event which has received increased attention recently due to reports of myocardial injury in a minority of patients following administration of messenger RNA (mRNA) based COVID-19 vaccines (4, 5) . As of December 2021, over 4.5 billion people worldwide have received a dose of COVID-19 vaccine (6) . Therefore, serious adverse events associated with administration of vaccines targeting COVID-19 are highly relevant to the public, clinicians, and other policy makers, even if the incidence is rare. Importantly, COVID-19 illness can also result in myocardial injury, which is associated with adverse outcomes in hospitalized patients, and should be balanced I n p r e s s The purpose of this study is to determine the pattern and extent of MRI findings in myocarditis associated with COVID-19 vaccination and to compare these findings to other causes of myocarditis.

This retrospective cohort study was approved by the institutional ethics committee and the requirement for written informed consent was waived. Consecutive adult (≥18 years of age) hospitalized or nonhospitalized patients who were referred to a tertiary hospital network for evaluation of myocarditis by cardiac MRI between December 2019 and November 2021 were identified. Inclusion criteria were fulfillment of 1) clinical presentation and diagnostic testing criteria of the European Society of Cardiology diagnostic criteria for clinically suspected myocarditis (13) and 2) both of the main revised Lake Louise criteria for non-ischemic myocardial inflammation on MRI (at least one T1-based criteria and at least one T2-based criteria, additional details in Appendix E1 (14) . Exclusion criteria included MRI performed for follow-up of previously diagnosed myocarditis.

Data on demographic characteristics, vaccine administration, medications, blood test results, ECG parameters, and clinical outcomes were extracted from the electronic patient record. Patients were classified into one of three groups: COVID-19 vaccine associated myocarditis (symptom onset within 14 days of vaccine administration with no other cause for myocarditis identified), COVID-19 illness associated myocarditis (symptom onset within 14 days of confirmed severe acute respiratory syndrome coronavirus 2 [SARS-COV-2] infection based on reverse-transcriptase-polymerase chain reaction assays of nasopharyngeal swabs with no other cause for myocarditis identified), and other myocarditis (all other patients meeting inclusion criteria without temporally associated COVID-19 vaccine administration or known COVID-19 illness) (15, 16) . Adverse cardiac events were evaluated at short-term follow-up, I n p r e s s including death, arrhythmia (defined as sustained atrial or ventricular arrhythmia lasting at least 30 seconds), and heart failure hospitalization. Clinically available blood tests including high sensitivity cardiac troponin I (hsTnI), B-type natriuretic peptide (BNP), and C-reactive protein (CRP) were collected.

Cardiac MRI studies were performed using 1.5 or 3 Tesla scanners (Magnetom AVANTOfit/SKYRAfit, Siemens Healthineers, Siemens, Germany) with commercially available cardiac surface coils. The MRI protocol included long-axis and a stack of short-axis balanced cine steady state-free precession (bSSFP) slices (slice thickness 8 mm and 2 mm inter-slice gap) and a stack of black-blood T2-weighted spectral attenuated inversion-recovery (SPAIR) images at matching short-axis locations. Late gadolinium enhanced (LGE) images were acquired using a 2D phase sensitive inversion recovery technique starting 12 minutes after administration of intravenous contrast (0. 15 and T2 maps were automatically generated on the scanner with application of inline motion correction algorithms.

MRI studies were analyzed independently by two experienced fellowship trained observers [author initials blinded for review] who were blinded to all clinical information using commercially available tools (Circle cmr42; Circle Cardiovascular Imaging, Calgary, Canada). Ventricular volumes, function, and mass were measured using semi-automated contour detection with manual correction if required as per I n p r e s s established standards (20). Global longitudinal, circumferential, and radial strain (GLS [3 long-axis views], GRS, and GCS [entire short-axis stack], respectively) were calculated from bSSFP images using feature tracking strain analysis. Presence of LGE and regional T2-weighted hyperintensity were evaluated visually (present or not) globally and according to the AHA 17-segment model (21). For assessment of LGE, the predominant pattern was classified as subendocardial, mid-wall, subepicardial, or transmural. LGE was quantified using a signal-intensity threshold of 4 standard deviations (SD) above visually normal reference myocardium, expressed in grams and as a percentage of left ventricular mass.

Source T1 and T2 mapping images were examined for artifacts and any segments with artifact were excluded from analysis. Septal T1 and T2 relaxation times were assessed by manually drawing a region of interest at the mid-interventricular septum avoiding the right ventricular insertion points and blood pool. Maximum T1 and T2 values were also measured by manually drawing a region of interest in areas of visually maximum myocardial values based on the color map, with a minimum region of interest size of 0.5 cm 2 . As per current guidelines, abnormal maximum T1 and T2 values were defined as 2 SD above the mean of sequence specific local reference values (high T2 defined as >52 ms at 1.5T and >45 ms at 3T; high T1 defined as >1067 ms at 1.5T and >1289 ms at 3T) (22). To facilitate combined analysis of multi-scanner data, T1 and T2 values were converted to a z-score using scanner-specific local reference values (patient value − mean of reference range)/(SD of reference range) (23). In this case, z-scores provide an assessment of how many SD each patient's T1 or T2 value is above or below the mean for the normal range for each scanner.

Categorical data are presented as counts (percentages) and continuous variables as means (standard deviation) and medians (interquartile ranges [IQRs]). All continuous data were tested for normal distribution using the Shapiro-Wilk test. Comparisons between groups were conducted using one-way I n p r e s s analysis of variance for continuous variables with normal distribution and Kruskal-Wallis test for continuous variables with non-normal distribution, with post hoc tests for significance between groups using Bonferroni correction. Fisher's exact test was used to compare categorical variables. We performed sensitivity analyses restricting the vaccine associated group to those without a prior history of COVID-19 infection and restricting the other myocarditis group to those with a non-COVID-19 viral/post-infectious cause of myocarditis. Spearman correlation analysis was used to evaluate associations between continuous variables. Linear regression was used to evaluate the relationship between continuous MRI parameters and patient group controlling for patient age, sex, and length of time from symptoms to MRI. All tests were 2-tailed, and P values less than .05 were considered statistically significant. Analysis was performed using STATA software v14.1 (StataCorp, College Station, Texas) and data were visualized with GraphPad Prism 9.0.2 (GraphPad Software, Inc., La Jolla, CA, USA).

Ninety-six patients were evaluated for eligibility. Four patients were excluded as MRI was performed for follow-up of previously diagnosed myocarditis ( Figure 1 ) leaving 92 patients (mean age, 41±18 years, 61% men), Table 1 . Twenty-one patients (23%) had COVID-19 vaccine associated myocarditis, of which 17 (81%) were male and mean (SD) age was 31 (14) The median [IQR] interval between symptom onset and MRI was 11 days.

Among patients with vaccine associated myocarditis, symptom onset followed administration of mRNA-1273 (Moderna) in 12 (57%) and BNT162b2 (Pfizer-BioNTech) in 9 (43%) and occurred after administration of the second vaccine dose of a 2-dose series in 17 patients (81%). Those who had received two doses had a median [IQR] interval between first and second doses of 33 [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] 

MRI characteristics are provided in Table 2 . Abnormal MRI findings among patients with myocarditis following COVID-19 vaccination included LGE in 17 (81%), high T1 in 14 (67%), high T2 in 16 (76%), hyperintense signal on T2-weighted imaging in 15 (79%), and systolic left ventricular dysfunction (LVEF <55%) in 6 (29%), Figure 2 . In all patients , at least one T2-based abnormality co-localized within the same myocardial segment as a T1-based abnormality, including LGE. None of the MRI parameters differed significantly between vaccine types.

Peak hsTnI correlated significantly with maximum native T2 z-score (r=0.50; P=.040), LVEF (r=-0.58; P=.015), GCS (r = 0.66; P = .005), and GRS (r = -0.59; P = .013), but not with maximum native T1 zscore, LGE extent, or GLS.

Compared with patients with other causes of myocarditis, patients with vaccine associated myocarditis had significantly higher LVEF and RVEF, less impaired GLS, GCS and GRS, lower native T1, and less extensive LGE, Figure 3 , Table 2 . Differences in LVEF, GLS, GCS, GRS, native T1, and LGE extent remained significant even after controlling for patient age, sex, and interval between symptom onset and imaging (Table 3 ). Compared to patients with COVID-19 illness, patients with vaccine associated myocarditis had higher LVEF, less regional wall motion abnormalities, and lower native T1. Differences in LVEF remained significant even in the multivariable model. In all three patient groups, the most frequent pattern of LGE was subepicardial and the most frequent myocardial segment involved was the basal inferolateral wall, Figure 4 . However, patients with COVID-19 illness and other myocarditis had a higher prevalence of abnormalities involving the basal to mid anterior and inferior septum, while patients with vaccine associated myocarditis rarely had abnormalities involving the anterior wall or septum. There were no significant differences in blood biomarkers or ECG parameters between groups.

Conclusions of our primary analyses were unchanged upon removing the 2 patients with vaccine associated myocarditis with a prior history of COVID-19 illness (Table E1 ) and when the other myocarditis group was restricted to patients with non-COVID-19 viral/post-infectious myocarditis (Table   E2 ).

All patients with vaccine associated myocarditis had short-term clinical follow-up with median [IQR] follow-up duration of 22 days. At follow-up, all 21 patients (100%) were asymptomatic, 8 (38%) had normal troponin levels, and 9 (43%) had reduced but still mildly elevated troponin levels (follow-up troponin levels were not available in 4 patients). Of the patients with impaired LVEF on MRI, 4/6 had subsequent transthoracic echocardiography or follow-up MRI which demonstrated normal LVEF in all.

No patient with vaccine associated myocarditis had an adverse cardiac event over short-term follow-up. implanted]). There were no deaths in any group. As expected, the follow-up duration for the other two groups was much longer than for the vaccine group, given the relatively short time interval over which COVID-19 vaccines have been administered.

In this retrospective cohort study of 92 patients meeting both clinical and imaging diagnostic criteria for acute myocarditis, we identified 21 patients with myocarditis following COVID-19 vaccine administration who were younger and more frequently male compared to 10 patients who had recovered from COVID- (10, 11, 24) . Other MRI findings in our cohort included high T1 and T2 mapping values and impaired myocardial strain. T1 and T2 mapping are quantitative tissue characterization techniques that provide complementary information, particularly in the setting of myocardial inflammation. High T2 is specific for increased tissue water and can discriminate between active and healed myocarditis (25) .

Native T1 is also elevated in the setting of edema, although unlike T2, this change is not specific for acute inflammation and can alternatively reflect fibrosis or infiltration. This might account for the significant correlation of peak troponin with native T2 but not with native T1 in our study.

Unlike prior reports, our findings also demonstrate that myocardial injury is detectable in patients with acute myocarditis not requiring hospital admission and that the severity of MRI abnormalities is milder in general compared to patients with other causes of myocarditis, even after controlling for age, sex and interval between symptom onset and imaging. Patients with myocarditis following COVID-19 illness had I n p r e s s lower LVEF, higher prevalence of regional left ventricular dysfunction, and higher native T1 compared to those with vaccine associated myocarditis, although other MRI parameters did not differ significantly.

This suggests that the imaging phenotype of patients with COVID-19 related myocardial injury may be intermediate between vaccine associated myocarditis and other causes. Milder MRI abnormalities in patients with vaccine associated myocarditis compared to other causes raises the possibility that this group may have a lower future adverse event rate. Lack of any adverse events in our patients with vaccine associated myocarditis over short-term follow-up is reassuring.

However, longer term follow-up is needed, particularly given the association of LGE with adverse cardiac events in non-vaccine associated myocarditis (28, 29) . Interestingly, one prior study found that patchy and mid-wall, but not subepicardial, patterns of LGE were associated with adverse events in patients with non-vaccine myocarditis (30) . Similarly, septal but not lateral LGE location was associated with major adverse cardiac events (30) . This requires further investigation given that the majority of patients with vaccine associated myocarditis in our study had a subepicardial pattern of LGE with a predilection for the basal to mid lateral wall and infrequent involvement of the septum, which may be associated I n p r e s s with relatively favorable outcomes. LGE usually reflects fibrosis in ischemic and non-ischemic cardiomyopathies; however, in patients with acute myocarditis it often reflects an increased volume of distribution of gadolinium-based contrast agent in the affected region related to myocyte necrosis and edema. In all patients with vaccine associated myocarditis, LGE co-localized with edema in at least one segment, which is associated with better prognosis compared to isolated LGE without T2-hyperintensity, and confers the possibility of recovery as edema improves with time (31).

Our study has limitations including a modest sample size and short-interval follow-up among patients with myocarditis following vaccination. More than one MRI scanner was used for imaging which impacts quantitative parametric mapping. To address this, we interpreted mapping values in the context of scanner specific local reference ranges and calculated z-scores for T1 and T2 values. The timing of MRI after symptom onset varied which could impact detection of myocardial edema, as MRI markers of edema typically demonstrate rapid improvement during the first few weeks after symptom onset (32) .

There were also significant differences in patient age and sex between groups. Although we adjusted for age, sex and timing of imaging in our analysis, it is possible that this did not fully account for differences between groups. Only mid-ventricular T1 and T2 mapping slices were examined, which could underestimate maximum T1 and T2 values if regional disease was only present in other areas of myocardium. However, LGE and T2-weighted imaging were performed with coverage of the entire myocardium from base to apex. This may account for the overall slightly higher prevalence of abnormalities on LGE and T2-weighted imaging compared to T1 and T2 mapping, respectively. As this was not a population-based study, we could not calculate the incidence of vaccine associated myocarditis. There is no standardized definition of vaccine associated myocarditis or COVID-19 related myocardial injury in the literature to date with respect to the timing of symptom onset after vaccine administration or COVID-19 diagnosis. For consistency, we used the same 14-day interval between I n p r e s s vaccination and COVID-19 diagnosis to symptom onset to define both groups. Finally, histologic confirmation of myocarditis was not available as endomyocardial biopsy is not frequently performed at our center unless there is clinical evidence that the results will have a meaningful effect on therapeutic decisions (33) . Our findings should be confirmed in future large, multi-center studies with longer term follow-up.

In conclusion, our study demonstrates that the pattern of MRI abnormalities in vaccine associated myocarditis is similar to other causes although patient demographics differ and MRI findings tend to be less severe. Overall, our study findings are generally consistent with an imaging phenotype with good prognosis; however, further studies are needed to examine the long-term effects of mRNA-based COVID-19 vaccination on the heart, determine the risk associated with booster doses, and inform recommendations for vaccination in patients with a history of myocarditis. I n p r e s s Maximum T2 z-score 0.5 (-0.9, 1.9) .48 0.4 (-0.3, 1.0) .25

LGE extent, number of segments 1.4 (-1.0, 3.6) .24 1.4 (0.3, 2.5) .011

Linear regression was used to evaluate the relationship between continuous MRI parameters and patient group in univariable models and in multivariable models controlling for patient age, sex, and length of time from symptoms to MRI. a Average difference in the magnitude of each MRI parameter (dependent variable) between myocarditis following COVID-19 illness and myocarditis following COVID-19 vaccination (independent variable, vaccine associated myocarditis is the reference group). b Average difference in the magnitude of each MRI parameter (dependent variable) between other causes of myocarditis and myocarditis following COVID-19 vaccination (independent variable, vaccine associated myocarditis is the reference group). c Individual multivariable linear regression models for each MRI parameter (as the dependent variable) and disease group (as the independent variable) were adjusted for patient age, sex, and interval between symptom onset and MRI.

Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination

A histopathologic definition and classification

Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis

Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS)

Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers

The New York Times Tracking Coronavirus Vaccinations Around the World

Characterization of Myocardial Injury in Patients With COVID-19

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Diagnostic Performance of Extracellular Volume, Native T1, and T2 Mapping Versus Lake Louise Criteria by Cardiac Magnetic Resonance for Detection of Acute Myocarditis: A Meta-Analysis

Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military

Myocarditis Associated with mRNA COVID-19 Vaccination

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations

COVID-19 Vaccination-Associated Myocarditis in Adolescents

Effects of age and sex on recovery from COVID-19: Analysis of

Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis

Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children

Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity

mRNA vaccine for cancer immunotherapy

mRNA vaccines -a new era in vaccinology

Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery

The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis

Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis

Prognostic Value of Repeating Cardiac Magnetic Resonance in Patients With Acute Myocarditis

Comprehensive Cardiac Magnetic Resonance for Short-Term Follow-Up in Acute Myocarditis

The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology

SUPPLEMENTAL REFERENCES

Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

According to these cardiac MRI criteria, fulfilment of at least one criterion in each of the following two categories is considered as strong evidence of acute myocardial inflammation in patients with high clinical pre-test probability: a T1-based marker of myocardial damage and a T2-based marker of myocardial edema (34) .

T1-criteria for myocardial damage: Late gadolinium enhancement (LGE) in a non-ischemic pattern or regional or global increase of myocardial native T1 relaxation time or extra-cellular volume (ECV).T2-based criteria for myocardial edema: Regional high T2-signal intensity or regional or global increase of myocardial T2 relaxation time.* Global T2 signal intensity ratio ≥2.0 on T2-weighted images is included in the updated Lake Louise criteria but was not evaluated in our study.* ECV is included in the updated Lake Louise criteria but was not evaluated in our study.

Systolic left ventricular dysfunction (either regional or global) and findings of pericardial inflammation (pericardial enhancement, high T1 or T2 mapping values, or the presence of a pericardial effusion) are considered supportive criteria, however neither are required to establish a diagnosis of myocarditis.

According to these diagnostic criteria, fulfilment of at least one clinical presentation and at least one diagnostic criteria from different categories is considered evidence of clinically suspected myocarditis, in the absence of angiographically detectable coronary artery disease (coronary stenosis ≥ 50%), and known pre-existing cardiovascular disease or extra-cardiac causes that could explain the presentation (35) . LGE extent, % 2 (1-5)

LGE extent, gramsLGE, number of LGE extent, % 2 (1-5) 1 (0-2) 2 (1-2) 6 (1-11) b .11

LGE extent, grams 2 (0-4) 1 (0-3) 2 (1-4) 4 (1-9) b .11LGE, number of I n p r e s s